Does Rallies show 13F holders for DXR?

Yes. Rallies tracks hedge fund and 13F ownership data for DXR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DXR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DXR. It does not provide personalized investment advice.

DXR (Daxor Corporation Common Stock) Stock Analysis - Hedge Fund Holdings

Daxor Corporation Common Stock (DXR) is a publicly traded Healthcare sector company. As of May 21, 2026, DXR trades at $11.35 with a market cap of $63.81M and a P/E ratio of 0.00. DXR moved +0.00% today. Year to date, DXR is -21.38%; over the trailing twelve months it is +50.73%. Its 52-week range spans $6.55 to $14.76. Analyst consensus is buy with an average price target of $22.50. Rallies surfaces DXR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DXR stock?

Hedge funds tracked by Rallies that own DXR include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Daxor Corporation Common Stock.

DXR Key Metrics

Key financial metrics for DXR
Metric	Value
Price	$11.35
Market Cap	$63.81M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.03%
52-Week High	$14.76
52-Week Low	$6.55
Volume	0
Avg Volume	0
Revenue (TTM)	$1.45M
Net Income	$-7.19M
Gross Margin	54.89%

Top Hedge Funds Holding DXR

Renaissance Technologies holds 27.82K shares of DXR, changed +87.71% as of Dec 31, 2024.

Latest DXR News

Daxor Validates BVA’s 20% Hourly Albumin Leak Detection in Heart Failure Study — Mar 26, 2026
Daxor Reports 45% Revenue Growth, NAV Per Share Hits $9.07 After FDA Clearance — Mar 3, 2026
Daxor Launches 98% Accurate BVA Outpatient Program in Tennessee with 24h Turnaround — Feb 24, 2026

Recent DXR Insider Trades

Feldschuh Michael Richard bought 1.00K (~$9.07K) on Apr 8, 2026.
Michel Robert J bought 1.00K (~$9.90K) on Mar 31, 2026.
Feldschuh Michael Richard bought 2.06K (~$16.28K) on Apr 4, 2025.

DXR Analyst Consensus

2 analysts cover DXR: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.50.

Common questions about DXR

Who owns DXR stock?: Hedge funds tracked by Rallies that own DXR include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Daxor Corporation Common Stock.
Does Rallies show 13F holders for DXR?: Yes. Rallies tracks hedge fund and 13F ownership data for DXR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DXR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DXR. It does not provide personalized investment advice.